Use of Total and Unbound Imatinib and Metabolite LC-MS/MS Assay to Understand Individual Responses in CML and GIST Patients

Abstract

The liquid-chromatography tandem-mass-spectrometry methods developed provided information useful to understand individual responses to therapy even though necessary sampling and dosing information was often not available. Wide unpredictable variations in t-IM, t-NDI, and f-IM were found. Clinical outcome trials are needed to examine whether f-IM or NDI monitoring can improve the ability to predict individual responses.